The role of chemokines in intestinal inflammation and cancer

Current Opinion in Pharmacology

Volumn 9, Issue 6, 2009, Pages 688-696

  Wang, Dingzhi ^a   DuBois, Raymond N ^a   Richmond, Ann ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c Department of Cancer Biology Vanderbilt ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA CHEMOKINE; B LYMPHOCYTE ANTIBODY; BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR3 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CLOTRIMAZOLE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; T LYMPHOCYTE ANTIBODY; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER RISK; CLINICAL TRIAL; COLITIS; COLON CARCINOMA; COLORECTAL CANCER; COLORECTAL SURGERY; CYTOKINE RELEASE; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INFLAMMATION; DRUG TARGETING; ENTERITIS; EOSINOPHIL; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LYMPH NODE METASTASIS; MACROPHAGE; MONOCYTE; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CHEMOKINES; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR BURDEN;

EID: 70449490252     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.08.003     Document Type: Review

References (88)

1. Kuper H., Adami H.O., and Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 248 (2000) 171-183
2. Smalley W.E., and DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39 (1997) 1-20
3. Lewis J.D., Deren J.J., and Lichtenstein G.R. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am 28 (1999) 459-477 x
4. Izzo A.A., and Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57 (2008) 1140-1155
5. Harrington L.E., Mangan P.R., and Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 18 (2006) 349-356
6. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13 (2007) 139-145
7. Neuman M.G. Immune dysfunction in inflammatory bowel disease. Transl Res 149 (2007) 173-186
8. Strober W., Fuss I., and Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 117 (2007) 514-521
9. Sands B.E. Inflammatory bowel disease: past, present, and future. J Gastroenterol 42 (2007) 16-25
10. Mahida Y.R. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6 (2000) 21-33
11. Gijsbers K., Geboes K., and Van Damme J. Chemokines in gastrointestinal disorders. Curr Drug Targets 7 (2006) 47-64
12. Danese S., and Gasbarrini A. Chemokines in inflammatory bowel disease. J Clin Pathol 58 (2005) 1025-1027
13. Alzoghaibi M.A., Al-Mofleh I.A., and Al-Jebreen A.M. Neutrophil chemokines GCP-2 and GRO-alpha in patients with inflammatory bowel disease. J Dig Dis 9 (2008) 144-148. Data indicate that serum levels of GROalpha (CXCL1) may serve as a biomarker for IBD.
14. Ina K., Kusugami K., Yamaguchi T., Imada A., Hosokawa T., Ohsuga M., Shinoda M., Ando T., Ito K., and Yokoyama Y. Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol 92 (1997) 1342-1346
15. Keates S., Keates A.C., Mizoguchi E., Bhan A., and Kelly C.P. Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol 273 (1997) G75-82
16. Z'Graggen K., Walz A., Mazzucchelli L., Strieter R.M., and Mueller C. The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology 113 (1997) 808-816
17. Gijsbers K., Van Assche G., Joossens S., Struyf S., Proost P., Rutgeerts P., Geboes K., and Van Damme J. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol 34 (2004) 1992-2000
18. Mitsuyama K., Tsuruta O., Tomiyasu N., Takaki K., Suzuki A., Masuda J., Yamasaki H., Toyonaga A., and Sata M. Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease. Dig Dis Sci 51 (2006) 173-177
19. Benelli R., Morini M., Carrozzino F., Ferrari N., Minghelli S., Santi L., Cassatella M., Noonan D.M., and Albini A. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16 (2002) 267-269
20. Thapa D., Lee J.S., Park S.Y., Bae Y.H., Bae S.K., Kwon J.B., Kim K.J., Kwak M.K., Park Y.J., Choi H.G., et al. Clotrimazole ameliorates intestinal inflammation and abnormal angiogenesis by inhibiting interleukin-8 expression through a nuclear factor-kappaB-dependent manner. J Pharmacol Exp Ther 327 (2008) 353-364. This in vivo study established an important role of IL-8 (CXCL8) in inflammation-induced angiogenesis.
21. Chakravarti A., Rusu D., Flamand N., Borgeat P., and Poubelle P.E. Reprogramming of a subpopulation of human blood neutrophils by prolonged exposure to cytokines. Lab Invest (2009)
22. Hawinkels L.J., Zuidwijk K., Verspaget H.W., de Jonge-Muller E.S., van Duijn W., Ferreira V., Fontijn R.D., David G., Hommes D.W., Lamers C.B., et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 44 (2008) 1904-1913
23. Romagnani S. Induction of TH1 and TH2 responses: a key role for the 'natural' immune response?. Immunol Today 13 (1992) 379-381
24. Singh U.P., Venkataraman C., Singh R., and Lillard Jr. J.W. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets 7 (2007) 111-123. Recent review of the role of CXCR3 axis in IBD.
25. -/- mice. J Immunol 171 (2003) 1401-1406
26. Seiderer J., Dambacher J., Leistner D., Tillack C., Glas J., Niess J.H., Pfennig S., Jurgens M., Muller-Myhsok B., Goke B., et al. Genotype-phenotype analysis of the CXCL16 p Ala181Val polymorphism in inflammatory bowel disease. Clin Immunol 127 (2008) 49-55
27. Mikami S., Nakase H., Yamamoto S., Takeda Y., Yoshino T., Kasahara K., Ueno S., Uza N., Oishi S., Fujii N., et al. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther 327 (2008) 383-392. This paper provides the first in vivo demonstration that the CXCL12/CXCR4 signals are involved in IBD progression.
28. Zhong W., Kolls J.K., Chen H., McAllister F., Oliver P.D., and Zhang Z. Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease. Front Biosci 13 (2008) 1654-1664
29. Khan W.I., Motomura Y., Wang H., El-Sharkawy R.T., Verdu E.F., Verma-Gandhu M., Rollins B.J., and Collins S.M. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am J Physiol Gastrointest Liver Physiol 291 (2006) G803-811
30. Andres P.G., Beck P.L., Mizoguchi E., Mizoguchi A., Bhan A.K., Dawson T., Kuziel W.A., Maeda N., MacDermott R.P., Podolsky D.K., et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 164 (2000) 6303-6312
31. Tokuyama H., Ueha S., Kurachi M., Matsushima K., Moriyasu F., Blumberg R.S., and Kakimi K. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol 17 (2005) 1023-1034
32. Lugering A., Kucharzik T., Soler D., Picarella D., Hudson III J.T., and Williams I.R. Lymphoid precursors in intestinal cryptopatches express CCR6 and undergo dysregulated development in the absence of CCR6. J Immunol 171 (2003) 2208-2215
33. Rivera-Nieves J., Ho J., Bamias G., Ivashkina N., Ley K., Oppermann M., and Cominelli F. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 131 (2006) 1518-1529
34. Yuan Q., Bromley S.K., Means T.K., Jones K.J., Hayashi F., Bhan A.K., and Luster A.D. CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med 204 (2007) 1327-1334. Animal studies in this paper show that CCR4-deficient T-reg cells fail to suppress the development of colitis, suggesting that CCR4 plays a key role in IBD.
35. Schneider M.A., Meingassner J.G., Lipp M., Moore H.D., and Rot A. CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 204 (2007) 735-745. This paper provides genetic evidence that CCR7 negative T-reg cells are less able to prevent the development of IBD than CCR7 positive T-reg cells.
36. Kaser A., and Tilg H. Novel therapeutic targets in the treatment of IBD. Expert Opin Ther Targets 12 (2008) 553-563
37. Rothenberg M.E., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
38. Ahrens R., Waddell A., Seidu L., Blanchard C., Carey R., Forbes E., Lampinen M., Wilson T., Cohen E., Stringer K., et al. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol 181 (2008) 7390-7399. In vivo experiments demonstrate that eosinophil recruitment is required for IBD and depends on CCL11.
39. Brand S., Olszak T., Beigel F., Diebold J., Otte J.M., Eichhorst S.T., Goke B., and Dambacher J. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem 97 (2006) 709-723
40. Varona R., Cadenas V., Flores J., Martinez A.C., and Marquez G. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur J Immunol 33 (2003) 2937-2946
41. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 4 (2004) 540-550
42. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
43. Baier P.K., Eggstein S., Wolff-Vorbeck G., Baumgartner U., and Hopt U.T. Chemokines in human colorectal carcinoma. Anticancer Res 25 (2005) 3581-3584
44. Speetjens F.M., Kuppen P.J., Sandel M.H., Menon A.G., Burg D., van de Velde C.J., Tollenaar R.A., de Bont H.J., and Nagelkerke J.F. Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res 14 (2008) 2276-2284
45. + CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer 8 (2008) 178. Clinical data from this paper show a correlation between CXCL1 and CXCL5 expression and the status of CRC.
46. Jiang W., Li X., Rao S., Wang L., Du L., Li C., Wu C., Wang H., Wang Y., and Yang B. Constructing disease-specific gene networks using pair-wise relevance metric: application to colon cancer identifies interleukin 8, desmin and enolase 1 as the central elements. BMC Syst Biol 2 (2008) 72
47. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., and Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133 (2008) 1019-1031
48. Watanabe H., Miki C., Okugawa Y., Toiyama Y., Inoue Y., and Kusunoki M. Decreased expression of monocyte chemoattractant protein-1 predicts poor prognosis following curative resection of colorectal cancer. Dis Colon Rectum 51 (2008) 1800-1805
49. Mumtaz M., Wagsater D., Lofgren S., Hugander A., Zar N., and Dimberg J. Decreased expression of the chemokine CCL21 in human colorectal adenocarcinomas. Oncol Rep 21 (2009) 153-158
50. Dimberg J., Hugander A., and Wagsater D. Protein expression of the chemokine, CCL28, in human colorectal cancer. Int J Oncol 28 (2006) 315-319
51. Allavena P., Sica A., Garlanda C., and Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222 (2008) 155-161. Excellent review covering the role of macrophages in tumor formation and progression.
52. Tsuchiyama T., Nakamoto Y., Sakai Y., Mukaida N., and Kaneko S. Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation. Cancer Sci 99 (2008) 2075-2082
53. Kim J., Takeuchi H., Lam S.T., Turner R.R., Wang H.J., Kuo C., Foshag L., Bilchik A.J., and Hoon D.S. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23 (2005) 2744-2753
54. Schimanski C.C., Schwald S., Simiantonaki N., Jayasinghe C., Gonner U., Wilsberg V., Junginger T., Berger M.R., Galle P.R., and Moehler M. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11 (2005) 1743-1750
55. Gunther K., Leier J., Henning G., Dimmler A., Weissbach R., Hohenberger W., and Forster R. Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int J Cancer 116 (2005) 726-733
56. Kawada K., Hosogi H., Sonoshita M., Sakashita H., Manabe T., Shimahara Y., Sakai Y., Takabayashi A., Oshima M., and Taketo M.M. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26 (2007) 4679-4688. The first report shows an involvement of CXCR3 in colon tumor metastasis.
57. Kollmar O., Scheuer C., Menger M.D., and Schilling M.K. Macrophage inflammatory protein-2 promotes angiogenesis, cell migration, and tumor growth in hepatic metastasis. Ann Surg Oncol 13 (2006) 263-275
58. Yoshitake N., Fukui H., Yamagishi H., Sekikawa A., Fujii S., Tomita S., Ichikawa K., Imura J., Hiraishi H., and Fujimori T. Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer 98 (2008) 1682-1689. Clinical data are provided in this paper showing that CXCL12 and CXCR4 may serve as biomarkers for CRC metastasis.
59. Lurje G., Zhang W., Schultheis A.M., Yang D., Groshen S., Hendifar A.E., Husain H., Gordon M.A., Nagashima F., Chang H.M., et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 19 (2008) 1734-1741. Clinical data in this paper show a relation between polymorphism of CXCL8 and risk of tumor recurrence of CRC patients treated with adjuvant chemotherapy.
60. Ohta M., Tanaka F., Yamaguchi H., Sadanaga N., Inoue H., and Mori M. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26 (2005) 41-47
61. Rubie C., Oliveira V., Kempf K., Wagner M., Tilton B., Rau B., Kruse B., Konig J., and Schilling M. Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol 27 (2006) 166-174
62. Sturm A., Baumgart D.C., d'Heureuse J.H., Hotz A., Wiedenmann B., and Dignass A.U. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 29 (2005) 42-48
63. Zipin-Roitman A., Meshel T., Sagi-Assif O., Shalmon B., Avivi C., Pfeffer R.M., Witz I.P., and Ben-Baruch A. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 67 (2007) 3396-3405
64. Li A., Varney M.L., and Singh R.K. Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype. Clin Exp Metastasis 21 (2004) 571-579
65. Bates R.C., DeLeo III M.J., and Mercurio A.M. The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 299 (2004) 315-324
66. Zeelenberg I.S., Ruuls-Van Stalle L., and Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63 (2003) 3833-3839
67. Vitale S., Cambien B., Karimdjee B.F., Barthel R., Staccini P., Luci C., Breittmayer V., Anjuere F., Schmid-Alliana A., and Schmid-Antomarchi H. Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 56 (2007) 365-372
68. Kitamura T., and Taketo M.M. Keeping out the bad guys: gateway to cellular target therapy. Cancer Res 67 (2007) 10099-10102
69. Dimberg J., Dienus O., Lofgren S., Hugander A., and Wagsater D. Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients. Int J Oncol 31 (2007) 97-102
70. Bailey C., Negus R., Morris A., Ziprin P., Goldin R., Allavena P., Peck D., and Darzi A. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis 24 (2007) 121-130
71. Itoh Y., Joh T., Tanida S., Sasaki M., Kataoka H., Itoh K., Oshima T., Ogasawara N., Togawa S., Wada T., et al. IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. Cytokine 29 (2005) 275-282
72. Meijer J., Ogink J., and Roos E. Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer 99 (2008) 1493-1501. This paper addresses the controversy with regard to the functional role of CXCR7. Using two different cancer cell lines, a ligand stated to be specific for CXCR7 was shown to stimulate the growth and chemotaxis of CT26 colon carcinoma and KEP1 mammary carcinoma cells. However, when CXCR7 expression was knocked down by siRNA, there was no effect on the growth or lung metastasis of subcutaneous xenografts of these tumor cell lines.
73. Kollmar O., Junker B., Rupertus K., Menger M.D., and Schilling M.K. Studies on MIP-2 and CXCR2 expression in a mouse model of extrahepatic colorectal metastasis. Eur J Surg Oncol 33 (2007) 803-811
74. Meijer J., Zeelenberg I.S., Sipos B., and Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 66 (2006) 9576-9582
75. Fushimi T., O'Connor T.P., and Crystal R.G. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res 66 (2006) 3513-3522
76. Nukiwa M., Andarini S., Zaini J., Xin H., Kanehira M., Suzuki T., Fukuhara T., Mizuguchi H., Hayakawa T., Saijo Y., et al. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol 36 (2006) 1019-1027
77. Hisada M., Yoshimoto T., Kamiya S., Magami Y., Miyaji H., Yoneto T., Tamada K., Aoki T., Koyanagi Y., and Mizuguchi J. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther 11 (2004) 280-288
78. Kanagawa N., Niwa M., Hatanaka Y., Tani Y., Nakagawa S., Fujita T., Yamamoto A., and Okada N. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int J Cancer 121 (2007) 2013-2022
79. Hou J.M., Zhao X., Tian L., Li G., Zhang R., Yao B., Deng H.X., Yang J.L., and Wei Y.Q. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing mice. Acta Pharmacol Sin 30 (2009) 355-363
80. Flanagan K., Glover R.T., Horig H., Yang W., and Kaufman H.L. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine 22 (2004) 2894-2903
81. Ju D.W., Tao Q., Cheng D.S., Zhang W., Zhang M., Hamada H., and Cao X. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther 7 (2000) 329-338
82. Strieter R.M., Burdick M.D., Mestas J., Gomperts B., Keane M.P., and Belperio J.A. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42 (2006) 768-778
83. Wen Y., Giardina S.F., Hamming D., Greenman J., Zachariah E., Bacolod M.D., Liu H., Shia J., Amenta P.S., Barany F., et al. GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1. Clin Cancer Res 12 (2006) 5951-5959
84. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., Richmond A., Strieter R., Dey S.K., and DuBois R.N. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203 (2006) 941-951
85. Guleng B., Tateishi K., Ohta M., Kanai F., Jazag A., Ijichi H., Tanaka Y., Washida M., Morikane K., Fukushima Y., et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65 (2005) 5864-5871
86. Tanaka S., Tatsuguchi A., Futagami S., Gudis K., Wada K., Seo T., Mitsui K., Yonezawa M., Nagata K., Fujimori S., et al. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut 55 (2006) 54-61
87. Zhang R., Tian L., Chen L.J., Xiao F., Hou J.M., Zhao X., Li G., Yao B., Wen Y.J., Li J., et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther 13 (2006) 1263-1271
88. Li G., Tian L., Hou J.M., Ding Z.Y., He Q.M., Feng P., Wen Y.J., Xiao F., Yao B., Zhang R., et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 11 (2005) 4217-4224